Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study

Viner, Russell; Booy, Robert; Johnson, Helen; Edmunds, W. John; Hudson, Lee; Bedford, Helen; Kaczmarski, E.B.; Rajput, Kaukab; Ramsay, Mary; Christie, Deborah

doi:10.1016/s1474-4422(12)70180-1

Cited by 171 publications

(147 citation statements)

References 19 publications

Supporting

Mentioning

129

Contrasting

Unclassified

Order By: Relevance

“…1 Group B meningococcal disease is a potentially devastating condition, with an average case fatality rate of 5.2% (data for England and Wales 2 ), and over a third of survivors are left with measurable functional deficits. 3 The incidence of laboratory-confirmed cases is about 1 per 100 000 population in England 4 and 0.33 per 100 000 population in Canada. 5 The recommendation of the United Kingdom Joint Committee on Vaccination and Immunisation that the 4CMenB vaccine be introduced into the routine UK immunization schedule should, if implemented, lead to a reduction in this morbidity and mortality.…”

mentioning

confidence: 99%

Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months

McQuaid

Snape

John

et al. 2015

CMAJ

View full text Add to dashboard Cite

Interpretation: Waning of immunity by 5 years of age occurred after receipt of the 4CMenB vaccine in infancy, even with an additional booster at 40 months. The 4CMenB vaccine is immunogenic and was fairly well tol erated by 5-year-old children, although injection-site pain was noteworthy. Trial registration: Clinical Trials.gov, no. NCT01027351 Abstract Research E216CMAJ, April 21, 2015, 187 (7) We present here the results of a follow-on study investigating the persistence of antibodies 18-20 months after the last dose in 5-year-old children previously immunized under a variety of schedules with 4CMenB vaccine or another investigational vaccine (recombinant protein serogroup B meningococcal [rMenB] vaccine), which lacks the outer membrane vesicle component of the 4CMenB vaccine. Since the original infant study, 7 4CMenB vaccine has emerged as the preferred vaccine, because addition of the outer membrane vesicle component improves the breadth of strain coverage; 8 however, the extension study continued follow-up for all of the original children, and all results are therefore presented here. MethodsThis phase 2, open-label, single-centre extension study ran from January 2010 to August 2012 and was approved by the Oxfordshire Research Ethics Committee B (reference 09/H0605/89).The primary immunogenicity objective of the extension study was to assess persistence of antibodies at 40 months of age, as reported previously. 9 Here, we present the secondary outcomes of antibody persistence at 60 months of age and the immunogenicity, safety and tolerability of a 2-dose catch-up regimen of 4CMenB vaccine administered at 60 and 62 months. ParticipantsIn the original infant study, 7 147 infants from the UK were recruited and randomly assigned, on a 2:2:1:1 ratio, to receive 4CMenB or rMenB vaccine at 2, 4, 6 and 12 months or to receive one of these vaccines at 12 months alone.Of these 147 infants, 70 participated in the 40-month extension study, 9 in which those who originally received 4 doses received 1 additional dose (at 40 mo) and those who originally received 1 dose received 2 additional doses (at 40 and 42 mo) of the vaccine originally received. These groups are referred to here as follows: 4CMenB 2, 4,6,12,40; rMenB 2,4,6,12,40; 4CMenB 12,40,42; and rMenB 12,40,42. A fifth group (referred to as 4CMenB 40,42) received 2 doses of 4CMenB vaccine only at 40 and 42 months. All of these children were invited to participate again at about 60 months of age, and an additional 50 healthy, vaccine-naive controls (referred to as 4CMenB 60,62) were recruited by mail. The study therefore included a total of 6 groups (see Figure 1).Exclusion criteria were as follows: any previous meningococcal vaccination or history of meningococcal disease, severe allergy to any component of the vaccine, and any serious chronic or progressive disease or suspected immune system impairment. Administration of other vaccines was not permitted within 30 days before or after meningococcal vaccination, with the exception of the influenza vaccine, which c...

show abstract

mentioning

confidence: 99%

Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months

McQuaid

Snape

John

et al. 2015

CMAJ

View full text Add to dashboard Cite

show abstract

“…IMD remains one of the leading infectious causes of death in children in Australia. Moreover, overseas studies indicate that 9% of children who survive IMD are left with major physical, cognitive and/or psychological disabilities, 17 and 50% of survivors of adolescent IMD experience major long-term sequelae including skin scarring, mobility difficulty, and speech and hearing problems. 18 Structured review of the management of individual IMD cases has been used to identify areas for improvement in the medical, laboratory and public health management of IMD cases 19 and has the potential to improve outcomes for people with IMD.…”

Section: Serogroup C Diseasementioning

confidence: 99%

Meningococcal disease in NSW, 1991–2011: trends in relation to meningococcal C vaccination

Passmore

Ferson

Tobin

2013

NSW Public Health Bull

View full text Add to dashboard Cite

show abstract

“…In a study of Canadian patients, the mortality rate of serogroup C meningococcal disease was 14% but a similar percentage of cases (15%) had sequelae, including scars following skin necrosis (12%), amputations (5%), hearing loss (2%), and renal failure (1%) 18) . Reductions in verbal and full scale IQ and intellectual function can occur not only in children with meningitis 19) but also in other recovered children who experienced severe illness and extended ICU stays. Developmental delay and difficult social integration, as well as their impact on families, contribute further to the overall impact of the disease.…”

Section: Clinical Featuresmentioning

confidence: 99%

“…20) . However, antibiotic resistance has become important in the context of contact chemoprophylaxis; quinolone resistance has become widespread in the U.S. so that it is no longer recommended for chemoprophylaxis and rifampin and ceftriaxone 19) . …”

Section: Clinical Featuresmentioning

confidence: 99%

Meningococcal Disease and Quadrivalent MenACWY-CRM Vaccine (Menveo®)

Tsai

2012

Korean J Pediatr Infect Dis

View full text Add to dashboard Cite

® (Novartis Vaccines and Diagnostics), a novel quadrivalent meningococcal conjugate vaccine directed against meningococcal serogroups A, C, W-135 and Y, has been shown to be immunogenic and well tolerated in all age groups and was recently licensed for use in Korea. Recent cases and deaths among military recruits drew public attention to their elevated risk and the Korean government has recommended vaccination of all new military recruits. Many Korean students seek to attend school, university, or language institutes in countries where routine meningococcal vaccination is required -clinicians should be aware of such requirements to ensure that students are vaccinated prior to arrival in the destination country. (Korean J Pediatr Infect Dis 2012;19:89-110)

show abstract

Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study

Cited by 171 publications

References 19 publications

Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months

Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months

Meningococcal disease in NSW, 1991–2011: trends in relation to meningococcal C vaccination

Meningococcal Disease and Quadrivalent MenACWY-CRM Vaccine (Menveo®)

Contact Info

Product

Resources

About